免疫检查点抑制剂治疗广泛期小细胞肺癌的研究进展
Advances in immune-checkpoint inhibitors for the treatment of extensive-stage small cell lung cancer
李珂 1秦博宇 1邵佳康 1邱鲁鹏 1孙小惠 1贾谷和 2焦顺昌1
作者信息
- 1. 100853 北京 解放军医学院研究生院;100071 解放军总医院第五医学中心肿瘤内科
- 2. 100853 北京 解放军医学院研究生院;300071 南开大学医学院临床医学系
- 折叠
摘要
小细胞肺癌(SCLC)约占肺癌病例的 15%,其生长迅速、恶性程度高、易远处转移,是临床最难治的疾病之一.经过几十年的研究,广泛期小细胞肺癌(ES-SCLC)患者的预后仍然很差.近年来,免疫检查点抑制剂(ICIs)的出现改变了ES-SCLC的治疗格局.目前,指南推荐ICIs联合含铂双药化疗用于ES-SCLC的一线治疗.但ICIs治疗ES-SCLC的体系尚未成熟,有关ICIs联合治疗方案的探索仍在进行.本文总结了ICIs在ES-SCLC中的治疗现状及进展,为探索ES-SCLC的最佳免疫治疗模式提供了思路.
Abstract
Objective Small cell lung cancer(SCLC),which accounts for approximately 15%of lung cancer cases,is one of the most difficult-to-treat diseases due to its rapid growth,high malignancy,and early distant metastasis.After decades of research,the prognosis of patients with extensive-stage small cell lung cancer(ES-SCLC)remains poor.In recent years,the emergence of immune-checkpoint inhibitors(ICIs)has changed the treatment landscape of ES-SCLC.Currently,guidelines recommend ICIs in combination with platinum-based double chemotherapy for the first-line treatment of ES-SCLC.However,the system of ICIs for the treatment of ES-SCLC is not yet mature,and the exploration of combination immunotherapies is still ongoing.This paper summarizes the current status and advances of ICIs in the treatment of ES-SCLC,and provides ideas for exploring the optimal immunotherapy modalities of ES-SCLC.
关键词
广泛期小细胞肺癌/免疫治疗/免疫检查点抑制剂/临床进展Key words
Extensive-stage small cell lung cancer/Immunotherapy/Immune-checkpoint inhibitors/Clinical develop-ment引用本文复制引用
出版年
2024
NETL
NSTL
万方数据